Early human studies of a new carbonic anhydrase inhibitor (NSD 3004) with anticonvulsant properties.
D000328:Adult; D000814:Aniline Compounds / Q000097:blood / Q000494:pharmacology; D000927:Anticonvulsants / Q000097:blood / Q000494:pharmacology*; D002257:Carbonic Anhydrase Inhibitors / Q000097:blood / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D004912:Erythrocytes / Q000032:analysis; D005260:Female; D006207:Half-Life; D006801:Humans; D007259:Infrared Rays; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D013057:Spectrum Analysis; D013449:Sulfonamides / Q000097:blood / Q000494:pharmacology*; D013450:Sulfones / Q000097:blood / Q000494:pharmacology
D000814:Aniline Compounds; D000927:Anticonvulsants; D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013450:Sulfones